ArticleFrontiers in medicine2026
Effects of Qishen Yiqi dropping pills plus conventional Western medicine on cardiac function and quality of life of patients with chronic heart failure.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To assess the impact of combining Qishen Yiqi dropping pills (QSYQ) with conventional Western medicine on the cardiac function and quality of life in patients with chronic heart failure (CHF). Methods: This was a randomized controlled trial (RCT), and 120 patients with CHF were recruited and randomly divided into the control group (receiving conventional Western medicine treatment) and study group (receiving QSYQ and conventional Western medicine treatment) at 1:1 ratio. The primary outcome was clinical efficacy, and the secondary outcomes were cardiac function, exercise tolerance, quality of life, inflammatory markers, and adverse reactions. Results: The study group demonstrated a higher total effective rate than the control group (91.67% vs. 70%, Conclusion: QSYQ combined with conventional Western medicine yielded a notable therapeutic effect on CHF, indicating that QSYQ may be an important adjuvant therapy for CHF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.